Study assesses relationship between conflicts of interest and voting patterns at FDA meetings (EurekAlert!)
Disclosures of conflicts of interest at Food and Drug Administration (FDA) drug advisory committee meetings are common, often of considerable financial value, and rarely result in the recusal of advisory committee members, but excluding those with conflicts would not have altered the overall vote outcome at any meeting, according to a study published in the April 26 issue of JAMA.

FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe Disease (PR Newswire via Yahoo! Finance)
Genzyme Corp. announced today that the Food and Drug Administration has granted marketing approval for Myozyme in the United States.